Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708 (NCT05317637)
๐ฉบ Plain-English Summary (8th-Grade Level)
Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms. The majority of cases is caused by a dominant mutation in type I collagen genes (COL1ฮฑ1 and COL1ฮฑ2), altering the quantity or quality of type I collagen. Although OI is typically characterized as a disease of the bone, it is perhaps more accurately described as a connective tissue disorder. Type I collagen is a major constituent of lung connective tissue. Respiratory insufficiency is the leading cause of death in patients with OI. Thus, it is important and necessary to understand the etiology of the restrictive pulmonary physiology in the OI population.
Who can join: Review the eligibility criteria below.
Location: University of California Los Angeles โ Los Angeles, California
Age range: 18 Years
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (3 Sites)
- University of California Los Angeles โ Los Angeles, California
- Kennedy Krieger Institute / Hugo W. Moser Research Institute โ Baltimore, Maryland
- Hospital for Special Surgery โ New York, New York
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Osteogenesis Imperfecta
- Dental Malocclusion and Craniofacial Development in OI โ Los Angeles, California
- Setrusumab vs Placebo for Osteogenesis Imperfecta โ Little Rock, Arkansas
- Clear Aligners for the Treatment of Dental Malocclusion in OI โ Los Angeles, California
- Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta โ Birmingham, Alabama
- Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta โ Phoenix, Arizona
Explore by condition: All Osteogenesis Imperfecta clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.